Resistance to apoptosis is one of the important determinants of resistance to 5-fluorouracil (5-FU) in colorectal cancer cells. Human Ring-Finger homologous to Inhibitor of apoptosis protein type (hRFI) is a newly discovered gene that has been shown to inhibit death receptormediated apoptosis in colorectal cancer cells. However, the molecular mechanism of the inhibition of apoptosis is presently unknown. In order to investigate the molecular function of hRFI in the regulation of 5-FU-induced apoptosis in colorectal cancer cells, HCT116 cells were stably transfected with hRFI or LacZ as a control. hRFI overexpression resulted in cellular resistance to 5-FU through an inhibition of the mitochondrial apoptotic pathway and specific upregulation of Bcl-2 and Bcl-XL. Futhermore, hRFI overexpression resulted in the activation of nuclear factor-jB (NF-jB). Inhibition of NF-jB effectively reversed the resistance to apoptosis as well as the upregulation of Bcl-2 and Bcl-XL in the hRFI transfectant, indicating that the activation of NF-jB is the key mechanism for all these findings. Overexpression of hRFI in SW480 and COLO320 colorectal cancer cells similarly resulted in resistance to 5-FU with the activation of NF-jB and upregulation of Bcl-2 and Bcl-XL. hRFI might be a novel therapeutic target for gene therapy in colorectal cancer.
Introduction 5-Fluorouracil (5-FU) is a chemotherapeutic agent widely used for the treatment of advanced colorectal cancer. Inducing apoptosis is one of the main mechanisms by which 5-FU eliminates cancer cells (Hwang et al., 2001; Rigas et al., 2002; Voboril et al., 2004) . On the other hand, advanced colorectal tumors are often resistant to such chemotherapy. Resistance to the induction of apoptosis is one of the most important determinants of chemoresistance to 5-FU (Korsmeyer, 1992; Miyashita and Reed, 1993; Violette et al., 2002) . Therefore, elucidation of the mechanism of cellular resistance to 5-FU-induced apoptosis is a critical issue requiring resolution to improve the survival of patients with advanced colorectal cancer.
hRFI (Accession no. AB084914), standing for 'human Ring-Finger homologous to Inhibitor of Apoptosis Protein (IAP) type', is a newly discovered gene that was isolated by means of a two-hybrid yeast screening method using hTID-1, an apoptosis regulator protein, as bait (Syken et al., 1999 (Syken et al., , 2003 Sasaki et al., 2002) . hRFI encodes a ring-finger domain highly homologous to that of X-chromosome-linked inhibitor of apoptosis protein (XIAP), which is the most potent IAP among the IAPs (Holcik et al., 2001; . hRFI also encodes a specific cleavage site targeted by caspase-3 at the residues 230-233 (Sasaki et al., 2002) . This structural evidence strongly supports a functional relationship of hRFI to the cell death pathway.
We have shown that hRFI is preferentially expressed in esophageal, gastric and colorectal cancers, suggesting a possible association between hRFI and the development of cancers of the digestive tract (Sasaki et al., 2002 (Sasaki et al., , 2003 (Sasaki et al., , 2004a . Especially in colorectal carcinogenesis, the expression of hRFI increases in the transition from the normal colorectal mucosa to adenoma, and from adenoma to carcinoma (Sasaki et al., 2004b) . This sequential upregulation of hRFI expression enables us to hypothesize that hRFI plays an essential role in colorectal carcinogenesis, probably related to its effects on antiapoptotic transformation. Indeed, our previous study revealed that exogenous overexpression of hRFI in colorectal cancer cells resulted in inhibition of the death receptor-mediated apoptosis induced by tumor necrosis factor-a (TNF-a) and tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) (Konishi et al., 2005) . However, the molecular mechanism of the inhibition of apoptosis by hRFI has not been fully clarified yet. Moreover, the antiapoptotic function of hRFI has been investigated only in death receptor-mediated apoptosis, and its effect on the mitochondrial apoptotic pathway is totally unknown. In this study, we investigated how the hRFI molecule can contribute to chemoresistance against 5-FU in colorectal cancer cells.
Results

Selection of HCT116 cells stably overexpressing hRFI
We previously demonstrated that the hRFI protein was expressed in colorectal cancer cell lines at variable levels (Konishi et al., 2005) . Among these cell lines, HCT116 cells exhibited a low level of hRFI expression, and thus were selected as the most appropriate cell type to examine the antiapoptotic function of hRFI by means of overexpression. Two HCT116 cell lines stably overexpressing hRFI (HCT116/RFI-high and HCT116/RFIlow) were established with the transfection of an expression vector containing the full-length cDNA of hRFI, and after selection with G418. Both of the cell lines exhibited increased expression of hRFI compared to control transfected with LacZ (HCT116/LacZ). The exogenously transfected hRFI protein with the V5-His tag was detected at a larger molecular weight than the native hRFI ( Figure 1a ). Proliferation assay revealed no significant differences in proliferation between these transfectants at 24, 48, 72, 96 and 120 h after plating (Figure 1b) .
Overexpression of hRFI inhibited 5-FU-induced apoptosis and increased the IC 50 values toward 5-FU In order to investigate whether hRFI expression affected the apoptosis induced by 5-FU, HCT116/RFI-high, HCT116/RFI-low and HCT116/LacZ cells were exposed to 3 mg/ml 5-FU for 48 h, and subjected to a nuclear staining assay. Propidium iodide (PI) positive apoptotic cells with typical apoptotic nuclei were significantly fewer in the HCT116/hRFI-high and HCT116/RFI-low cells than the HCT116/LacZ cells (Figure 2a) . In order to quantify the apoptosis rates, these cells were exposed to 5-FU under various concentrations, and were analysed for the apoptosis rate after double-staining with AnnexinV-FITC and PI using flowcytometry. As shown in Figure 2b , the apoptosis rate was increased in a dosedependent manner in all three transfectants. However, the apoptosis rate was significantly decreased in the HCT116/RFI-low cells compared to the HCT116/LacZ cells, and was further reduced in the HCT116/RFI-high transfectants. These results indicate that the apoptosis rate was inversely proportional to the expression level of hRFI. In order to determine whether hRFI expression affected chemosensitivity towards 5-FU, the inhibitory concentration of 50% proliferation (IC 50 ) values at 48 h were determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay in those three transfectants. As shown in Figure 2c , the IC 50 values of the HCT116/RFI-high and -low cells were nearly four times, and more than twice, higher than those of the HCT116/ LacZ cells, respectively (Po0.01 and 0.05, respectively, by one-way ANOVA). These results indicate that the overexpression of hRFI enhances chemoresistance to 5-FU through the inhibition of apoptosis in HCT116 colorectal cancer cells.
Overexpression of hRFI inhibited 5-FU-induced cytochrome c release from mitochondria and reduced activation of caspase-3 and -9 5-FU induces apoptosis in colorectal cancer cells predominantly through the mitochondrial apoptotic pathway (Sun et al., 2002) , which includes cytochrome c release from mitochondria into the cytosol (Kluck et al., 1997; Li et al., 1997; Green and Reed, 1998; Martinou et al., 2000) . In order to determine whether the antiapoptotic effect of hRFI was associated with this key step in the mitochondrial apoptotic pathway, the cytosolic cytochrome c protein was evaluated by Western blotting in cytosolic extracts of three transfectants with or without exposure to 5-FU. As shown in Figure 3a , cytochrome c release from mitochondria could be detected in the cytosolic fraction of all three transfectants treated with 5-FU. However, cytochrome c release was evidently decreased in the HCT116/RFI-low Figure 1 (a) Western blot analysis of hRFI expression in HCT116 cells stably transfected with hRFI or LacZ. HCT116 cells were transfected with hRFI or LacZ, and the cells resistant to G418 were isolated and analysed for the hRFI protein by Western blot. Two hRFI transfectant clones with different expression levels were isolated. The exogenously transfected hRFI protein with the V5-His tag was detected at a larger molecular weight (upper arrow) than the native hRFI (lower arrow). A rabbit anti-hRFI polyclonal antibody and a mouse anti-V5-HRP monoclonal antibody were used. A mouse anti-b-actin monoclonal antibody was used as a loading control. (b) Proliferation assay revealed no significant differences between these transfectants.
hRFI enhances chemoresistance to 5-FU T Konishi et al cells compared to the HCT116/LacZ cells, and the HCT116/RFI-high cells exhibited a further decrease of cytochrome c release. Events downstream of cytochrome c include caspase-9 and -3 activation. Caspase-9 is an initiator caspase that is triggered by cytochrome c and Apaf1 binding, and when activated, cleaves and activates caspase-3 (Kluck et al., 1997; Li et al., 1997; Martinou et al., 2000) . Therefore, in order to determine whether the antiapoptotic effect of hRFI was associated with the reduced activation of these caspases, we measured the activity of caspase-3 and -9. As expected from cytochrome c release, both the caspase-3 and -9 activities were significantly decreased in the hRFI transfectants, and the caspase activities were inversely proportional to the expression level of the hRFI protein (Figure 3b) . A threefold decrease of caspase-9 and -3 activity was detected in the HCT116/RFI-high cells compared to LacZ control after treatment with 3 mg/ml 5-FU for 48 h.
Overexpression of hRFI induced specific upregulation of Bcl-2 and Bcl-XL In order to investigate the molecular mechanism of the antiapoptotic properties of hRFI, the expression of various apoptosis regulator proteins, belonging to the Bcl-2 or IAP family, was examined in three transfectants by Western blotting of whole lysates. As shown in Figure 4a , the expression of Bcl-2 and Bcl-XL proteins was upregulated in proportion to the overexpression of the hRFI protein, whereas the expression of the other Bcl-2 (Bax, Bak, Bad, Bid and Mcl-1) and IAP family proteins (XIAP, cIAP-1, cIAP-2 and survivin) was not altered. In order to investigate whether this upregulation of the Bcl-2 and Bcl-XL proteins was also associated with an upregulation of mRNA, real-time PCR analysis of Bcl-2 and Bcl-XL was performed in those three transfectants. As shown in Figure 4b , both the Bcl-2/ GAPDH ratio and the Bcl-XL/GAPDH ratio were higher in proportion to hRFI expression, indicating that overexpression of hRFI induced an upregulation of mRNA as well as the protein level of Bcl-2 and Bcl-XL. In order to determine whether this upregulation of Bcl-2 and Bcl-XL is the crucial determinant of resistance to 5-FU-induced apoptosis in these transfectants, we assessed the effect of siRNA downregulation of Bcl-2 and Bcl-XL on apoptosis sensitivity. As shown in Figure 4c , siRNA towards Bcl-2 or Bcl-XL effectively downregulated the expression of each gene compared to the control siRNA. Then, the cells were exposed to 5-FU after siRNA downregulation of Bcl-2 or Bcl-XL, and the apoptosis rate was analysed using flowcytometry. As shown in Figure 4d , both siRNAs significantly increased the apoptosis rate compared to control, indicating that both Bcl-2 and Bcl-XL are important determinants of apoptosis sensitivity towards 5-FU in hRFI enhances chemoresistance to 5-FU T Konishi et al et al., 2004) . In order to investigate whether the upregulation of Bcl-2 and Bcl-XL in hRFI transfectants is associated with NF-kB activation, we measured the DNA-binding activity of NF-kB in the nuclear fraction of these three transfectants. As shown in Figure 5a , electrophoretic mobility shift assay (EMSA) revealed that the DNA-binding activity of NF-kB was increased in proportion to the overexpression of the hRFI protein.
Furthermore, ELISA-based assay revealed that p50 and p65 were activated in the hRFI-overexpressing cells, while the activity of the other NF-kB family members was not altered ( Figure 5b ). Next, we investigated the transcriptional activity of NF-kB by luciferase reporter assay. As shown in Figure 5c , the transcriptional activity of NF-kB in HCT116/RFI-high cells exhibited approximately threefold increase compared to HCT116/LacZ cells. Thus, the DNA-binding and transcriptional activity of NF-kB was increased in proportion to hRFI overexpression.
NF-kB inhibitor reversed the acquired resistance to apoptosis and the upregulation of Bcl-2 and Bcl-XL in hRFI transfectants In order to investigate whether the activation of NF-kB was responsible for the resistance to 5-FU-induced apoptosis in hRFI transfectants, cells were exposed to 5-FU after pretreatment with Bay11-7085, which selectively and irreversibly inhibits the induced phosphorylation of IkB without affecting the constitutive IkB-a phosphorylation (Pierce et al., 1997) . As shown in Figure 6a , NF-kB was activated by 5-FU exposure in all three transfectants, but Bay11-7085 effectively inhibited activation of NF-kB. Subsequently, the apoptosis rate was examined in these cells using flowcytometry. As shown in Figure 6b , the addition of Bay11-7085 restored apopotic sensitivity in the hRFI-overexpressing cells to the similar level as control. Finally, we investigated whether this re-sensitization to 5-FU-induced apoptosis by an NF-kB inhibitor was associated with the downregulation of Bcl-2 and Bcl-XL. hRFI transfectants were exposed to 5-FU with or without Bay11-7085 pretreatment, and the mRNA expression of Bcl-2 and Bcl-XL was determined by real-time PCR. As shown in Figure 6c , the expression level of Bcl-2 and Bcl-XL was increased by exposure to 5-FU in all three transfectants, and the upregulation of Bcl-2 and Bcl-XL in proportion to hRFI overexpression was not altered even after 5-FU stimulation. However, the addition of Bay11-7085 effectively reversed the upregulation of both Bcl-2 and Bcl-XL with or without 5-FU exposure, resulting in similar expression levels in these three transfectants. These findings indicate that NF-kB activation is responsible for the upregulation of Bcl-2 and Bcl-XL as well as the resistance to 5-FU in the hRFI transfectants.
Overexpression of hRFI inhibited 5-FU-induced apoptosis with an activation of NF-kB and upregulation of Bcl-2 and Bcl-XL in SW480 and COLO320 cells In order to investigate whether the antiapoptotic effect of hRFI is restricted to HCT116 cells, two colorectal cancer cells, SW480 and COLO320, were transiently transfected with an expression vector containing either hRFI or LacZ as a control. As shown in Figure 7a , Western blotting revealed that hRFI was overexpressed 24 h after transfection. Next, we examined the binding activity of NF-kB in the nuclear fraction of those transfectants with or without Bay11-7085 pretreatment by EMSA. As shown in Figure 7b , hRFI overexpression resulted in the activation of NF-kB compared to control, but Bay11-7085 effectively inhibited this activation. Furthermore, Western blotting revealed that the protein expression of Bcl-2 and Bcl-XL was upregulated in the cells overexpressing hRFI, but this upregulation was also reversed by the addition of Bay11-7085 (Figure 7b ). Finally, those transfectants were exposed to 5-FU with or without Bay11-7085 pretreatment, and the apoptosis rate was examined using flowcytometry. As shown in Figure 7c , the apoptosis rate was decreased in hRFI transfectants compared to control, but the addition of Bay11-7085 effectively reversed the resis- 
Discussion
In this study, we found that stable overepression of hRFI in HCT116 human colorectal cancer cells enhances chemoresistance to 5-FU through an inhibition of apoptosis. This apoptosis inhibition was accompanied by an evident decrease in cytochrome c release from the mitochondria and a reduced activity of caspase-3 and -9. Moreover, it was revealed that the overexpression of hRFI resulted in specific upregulation of Bcl-2 and Bcl-XL, although the expression levels of the other Bcl-2 family and IAP family members remained unchanged. We also elucidated that the overexpression of hRFI promotes the activation of NF-kB, and its inactivation effectively reverses both the resistance to 5-FU-induced apoptosis and the upregulation of Bcl-2 and Bcl-XL in hRFI-overexpressing cells. Finally, we confirmed that the findings are reproducible in other colorectal cancer cell lines, SW480 and COLO320. This is the first report to demonstrate that the hRFI molecule elicits acquired chemoresistance in carcinoma cells, possibly through the NF-kB-dependent regulation of the Bcl-2 family molecules.
5-FU induces apoptosis in colorectal cancer cells predominantly through the mitochondrial apoptotic pathway (Sun et al., 2002) , which involves the release of cytochrome c, and the subsequent activation of the upstream initiator caspase-9 and the downstream effecter caspase-3 (Kluck et al., 1997; Li et al., 1997; Green and Reed, 1998; Martinou et al., 2000) . We found that overexpression of hRFI attenuated all of these events in 5-FU-treated colorectal cancer cells. These findings clearly indicate that hRFI inhibits the mitochondrial apoptotic pathway in colorectal cancer cells. On the other hand, we have also found that the expression of Bcl-2 and Bcl-XL were upregulated in hRFI transfectant, and this upregulation was observed even after the exposure to 5-FU. Bcl-2 and Bcl-XL are the antiapoptotic members of the Bcl-2 family, sharing the conserved Bcl-2 homology (BH) regions BH1, BH2 and BH3 (Fesik, 2000; Huang and Strasser, 2000; Cory and Adams, 2002; Yang and Yu, 2003) . Evidence indicates that Bcl-2 and Bcl-XL act as stabilizers of mitochondrial membrane integrity by blocking the release of cytochrome c and subsequent caspase-9 and -3 activation, thus regulating the mitochondrial apoptotic pathway (Korsmeyer, 1992; Kluck et al., 1997; Martinou et al., 2000; Tsujimoto, 2000; . These effects comprise the main mechanism by which Bcl-2 and Bcl-XL inhibit the induction of apoptosis by a variety of chemotherapeutic agents hRFI enhances chemoresistance to 5-FU T Konishi et al including 5-FU (Miyashita and Reed, 1993; Reed et al., 1996; Nita et al., 2000; Sun et al., 2002; Violette et al., 2002) . In compatible with this evidence, the present study has revealed that siRNA downregulation of either Bcl-2 or Bcl-XL prominently increases 5-FU-induced apoptosis, indicating that both Bcl-2 and Bcl-XL are crucial determinants of the apoptosis sensitivity towards 5-FU in HCT116 cells. Considering the previous reports and our findings together, the upregulation of Bcl-2 and Bcl-XL should play an important role in the mechanism by which hRFI attenuates cytochrome c release, reduces caspase-9 and -3 activity and inhibits apoptosis in 5-FUtreated colorectal cancer cells.
Previous reports demonstrated that NF-kB is an important transcriptional regulator of Bcl-2 and Bcl-XL (Mori et al., 2001; Sevilla et al., 2001; Bharti and Aggarwal, 2002; Beinke and Ley, 2004; Panwalkar et al., 2004) . NF-kB is a family of transcription factors composed of homo-and heterodimers of Rel family polypeptides: p50, p52, RelA (p65), RelB and c-Rel (Rel) (Bharti and Aggarwal, 2002; Beinke and Ley, 2004; Panwalkar et al., 2004) . In non-simulated cells, NF-kB is inactivated by binding to IkB in the cytoplasm. On apoptotic stimulation, however, proteolytic degradation of IkB unmasks a nuclear target sequence within NF-kB and leads to its translocation to the nucleus, where it induces transcription of various genes, including antiapoptotic Bcl-2 and Bcl-XL (Baldwin, 1996; Pahl, 1999; Catz and Johnson, 2001; Bharti and Aggarwal, 2002; Beinke and Ley, 2004; Panwalkar et al., 2004) . The p50/RelA (p65) heterodimer, 'specifically' known as NF-kB, is the most common dimer, and the most important transcriptional regulator playing a major antiapoptotic role in anticancer drug-treated mammalian cells (Baeuerle and Henkel, 1994; Ghosh et al., 1998; Panwalkar et al., 2004) . Recent studies have demonstrated that NF-kB activation is closely correlated with resistance to the apoptosis induced by various chemotherapeutic agents in colorectal cancer cells, including 5-FU (Cusack et al., 2000; Voboril et al., 2004) . We found that hRFI overexpression increased both the binding and transcriptional activity of NF-kB with specific activation of p50 and RelA (p65). Furthermore, an NF-kB inhibitor effectively reversed the hRFI-mediated antiapoptotic transformation against 5-FU as well as the upregulation of Bcl-2 and Bcl-XL. These findings clearly suggest that hRFI is a new upstream regulator of NF-kB activation, and that the activation of NF-kB is the key mechanism by which hRFI elicits the upregulation of Bcl-2 and Bcl-XL and the subsequent inhibition of 5-FU-induced mitochondrial apoptotic pathway.
The molecular mechanism by which hRFI activates NF-kB remains unknown at this point. However, one possible mechanism might be the ubiquitination of IkB. It has been demonstrated that ubiquitination plays an important role in the proteosomal degradation of IkB, which leads to subsequent activation of NF-kB (Beinke Figure 7 Effects of hRFI overexpression on the activity of NF-kB, the expression of Bcl-2 and Bcl-XL, and the apoptosis induced by 5-FU in SW480 and COLO320 cells. (a) Western blotting revealed that hRFI was transiently overexpressed in SW480 and COLO320 cells 24 h after transfection. (b) Twenty-four hours after transfection, cells were treated with or without 2 mM Bay11-7085 under serumfree conditions for 1 h, and then maintained in normal growth medium for additional 24 h. EMSA revealed activation of NF-kB in the cells overexpressing hRFI, but the addition of Bay11-7085 effectively inhibited the activation of NF-kB. Western blotting revealed that the protein expression of Bcl-2 and Bcl-XL was upregulated in the hRFI transfectants, but Bay11-7085 effectively reversed the upregulation of both Bcl-2 and Bcl-XL. (c) Cells were similarly pretreated with or without Bay11-7085, and then exposed to 10 mg/ml (SW480) or 3 mg/ml (COLO320) 5-FU for 24 h. Flowcytometry analysis revealed that the apoptosis rate was decreased in hRFI transfectants, but the addition of Bay11-7085 effectively reversed the antiapoptotic effect of hRFI. Columns and bars indicate the mean and s.d. of values independently repeated three times in triplicate. *significance at Po0.05 by one-way ANOVA.
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and Ley, 2004; Panwalkar et al., 2004) . On the other hand, the ring-finger domain of IAP proteins possesses the ubiquitin ligase activity, which mediates the proteosomal degradation of various apoptosis regulators Yang et al., 2000; MacFarlane et al., 2002) . Considering that the ring-finger domain of hRFI possesses a high homology to that of XIAP (Sasaki et al., 2002) , hRFI might have ubiquitin ligase activity, which degrades IkB and leads to subsequent NF-kB activation. Finally, the apoptosis regulators are known to be closely related to both chemosensitivity and prognosis in colorectal cancer (Kahlenberg et al., 2003) . In particular, the expression of Bcl-2 family proteins is an important determinant of the chemosensitivity to 5-FU in colorectal cancer cells (Maurer et al., 1998; Ogura et al., 1999; Nita et al., 1998 Nita et al., , 2000 Violette et al., 2002) . We have revealed in this study that hRFI overexpression in colorectal cancer cells elicits an increase of IC 50 values towards 5-FU as well as the specific upregulation of Bcl-2 and Bcl-XL. Considering that the hRFI protein is diffusely expressed in colorectal cancer tissues as well as colorectal cancer cell lines (Sasaki et al., 2004b; Konishi et al., 2005) , hRFI is evidently one of the important determinants of 5-FU sensitivity in colorectal cancer through its effect on the regulation of apoptosis. hRFI might be a novel predictive marker for chemosensitivity, and a new therapeutic target for gene therapy in colorectal carcinomas.
Materials and methods
Cells, culture conditions and antibodies
All cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). HCT116 was maintained in McCoy's 5A modified medium (Invitrogen, Carlsbad, CA, USA), and other cell lines were in DMEM (Sigma), supplemented with 10% FBS (Sigma, Saint Louis, MO, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies Inc., Grand Island, NY, USA) at 371C in a humidified 5% CO 2 atmosphere. A rabbit anti-hRFI polyclonal antibody was generated previously (Sasaki et al., 2002) . A mouse anti-V5 monoclonal antibody was purchased from Invitrogen; a mouse anti-b-actin monoclonal antibody from Sigma: a mouse anti-Bad, Bak, cIAP-1, cytochrome c, XIAP monoclonal antibody from BD Biosciences (San Diego, CA, USA): a mouse anti-Bax, Bcl-XL, Mcl-1 monoclonal antibody and a rabbit anti-cIAP-2 polyclonal antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA): a rabbit anti-survivin polyclonal antibody from R&D Systems (Minneapolis, MN, USA), a mouse anti-Bid monoclonal antibody from Cell Signaling Technology (Beverly, MA, USA); a mouse anti-Bcl-2 monoclonal antibody from Dako Cytomation Denmark A/S (Glostrup, Denmark) and a mouse anti-cytochrome c oxidase IV (COX IV) monoclonal antibody from Abcam (Cambridge, UK).
Transient or stable transfection of hRFI Transfection of hRFI was performed as described previously (Konishi et al., 2005) . Briefly, the full-length cDNA of hRFI was subcloned into a pcDNA3.1/V5-His vector (Invitrogen), and the cells were transfected with 2 mg/ml plasmids using 5 mg/ ml Lipofectin (Invitrogen) in a serum-free OPTIMEM medium (Invitrogen) according to the manufacturer's protocol. For stable overexpression, cells were trypsinized 24 h after transfection and were incubated in the presence of 1000 mg/ml G418 (BD Biosciences, Palo Alto, CA, USA) for 2-3 weeks. Individual G418-resistant colonies were isolated and maintained in the presence of G418.
Western blotting
Western blotting was performed as described previously (Konishi et al., 2005) . Briefly, 20 mg aliquots of whole-cell lysates were electrophoresed in 15% Ready Gel J (Bio-Rad, Hercules, CA, USA). Separated proteins were electrophoretically transferred to a Hybond ECL nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, England) and incubated with each antibody. Proteins were detected and visualized with the ECL detection system (Amersham Pharmacia Biotech).
Proliferation assay
Cells were seeded in 96-well plates at a density of 2 Â 10 3 /well, and the proliferative activity at 24, 48, 72, 96 and 120 h after seeding was determined by MTS assay according to the manufacturer's instructions (CellTiter 96 Non-Radioactive Cell Proliferation Assay; Promega, Madison, WI, USA), to monitor the number of viable cells. All experiments were independently repeated three times in triplicate. Values for 50% inhibition (IC 50 values) were determined by log-logit curve fitting. The statistical difference of the logarithmic average of the IC 50 values was evaluated by one-way ANOVA.
Nuclear staining assay Cells were plated 24 h before 5-FU treatment. After apoptosis induction, cells were harvested by trypsinization, and fixed with 70% ethanol. Fixed cells were treated with 0.5% Tween 20 and stained with 0.5 mg/ml PI for 15 min. Nuclear morphology was examined by fluorescence microscopy.
Flowcytometry analysis of apoptosis
Cells were plated at a density of 1 Â 10 5 /well in six-well plates 24 h before the induction of apoptosis. After treatment with 5-FU for 48 h, cells were harvested by trypsinization, and doublestained with AnnexinV-FITC and (PI) using an AnnexinV-FITC Apoptosis Detection Kit (BioVision Research Products, Mountain View, CA, USA) according to the manufacturer's protocol. Samples were immediately analysed using a Becton Dickinson FACScan with CELLQuest software (Franklin Lakes, NJ, USA). The apoptosis rate was defined as the percentage of the AnnexinV-FITC-positive cells. All experiments were independently repeated three times in triplicate.
Analysis of cytochrome c release from mitochondria
Floating and attached cells were collected after incubation with or without 3 mg/ml 5-FU for 48 h, and the cytosolic fraction of the cells was isolated using a Mitochondrial/ Cytosol Fractionation Kit (BioVision Research Products) according to the manufacturers protocol. Cytochrome c release into the cytosol from mitochondria was determined by Western blotting, using a mouse anticytochrome c antibody. COX IV antibody was used as a control for purity of cytosolic fractions.
Flowcytometry analysis of the caspase activity Cells were plated at a density of 1 Â 10 5 /well in six-well plates 24 h before the induction of apoptosis. After treatment with 5-FU, cells were harvested by trypsinization, and the caspase-3 and -9 activity was determined using a caspase-3, -9 Detection Kit (Calbiochem, Darmstadt, Germany), respectively, accordhRFI enhances chemoresistance to 5-FU T Konishi et al ing to the manufacturer's protocol. Samples were immediately analysed using a Becton Dickinson FACScan with CELLQuest software. All experiments were independently repeated three times in triplicate.
Real-time PCR analysis RNA was prepared using the SV total RNA Isolation System (Promega, Madison, WI, USA) according to the manufacturer's protocol. Real-time PCR analysis was performed using the Applied Biosystems 7300 real-time PCR System instrument and software (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. After incubation for 2 min at 501C, 30 min at 601C and 5 min at 951C, each of the 40 PCR cycles consisted of 15 s of denaturation at 951C and hybridization of the probe and primers for 1 min at 601C. The original input RNA amounts were calculated with relative standard curves for both the RNAs of interest and the GAPDH control. Triplicate assays were performed with RNA samples obtained from three independent experiments. Gene expression values are reported as the normalized quotient derived by dividing each single gene copy number by the GAPDH copy number. The primers used in the analysis of Bcl-2 and Bcl-XL were Assays on Demand Products (Hs0060023_m1 for Bcl-2, Hs00236329_m1 for Bcl-XL; Applied Biosystems). The analysis of GAPDH was performed using TaqMan GAPDH Control Reagents (Applied Biosystems).
siRNA downregulation of Bcl-2 and Bcl-XL The siRNAs used in the experiments were silencer pre-designed siRNA no. 214533 for Bcl-2, no. 120718 for Bcl-XL and Silencer Negative Control no. 1 for the control (Ambion, Austin, TX, USA). Cells were seeded in 6-well plates at a density of 1 Â 10 5 /well 24 h before transfection. Then, cells were transfected with 50 nM siRNA oligonucleotides using Lipofectamine and Plus Reagents (Invitrogen) according to the manufacturer's protocol. Each assay was performed 48 h after the transfection of siRNAs.
NF-kB DNA-binding assay NF-kB DNA-binding activity was assessed with trans-active motif NF-kB family transcription factor assay kits (Active Motif Europe, Rixensart, Belgium) according to the manufacturer's protocol. This ELISA-like test measures the level of the active form of NF-kB contained in cell extracts specifically able to bind to an oligonucleotide containing the NF-kB consensus site (5 0 -GGGACTTTCC-3 0 ) attached to a 96-well plate (Renard et al., 2001) . Nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents and Halt Protease Inhibitor Cocktail Kit (Pierce Biomedical Company) according to the manufacturer's instructions, and 10 mg extracts were added to the 96-well plates. The binding of NF-kB to the DNA was visualized by anti-p50, anti-p52, antiRelA (p65), anti-RelB and anti-c-Rel (Rel) antibodies that specifically recognize activated NF-kB. Antibody binding was determined as absorbance values at 450 nm. All experiments were independently repeated three times in triplicate.
Electrophoretic mobility shift assay
The sequence of the DNA probe for the NF-kB binding site was 5 0 -AGTTGAGGGGACTTTCCCAGGC-3 0 (Harada et al., 1994) . The DNA probe was biotin-labeled using a Biotin 3 0 -End DNA Labeling Kit (Pierce Biomedical Company) according to the manufacturer's instruction. Nuclear extracts obtained as described in the previous section were mixed with the Biotin-labeled DNA probe using a LightShift Chemiluminescent EMSA Kit (Pierce Biomedical Company) according to the manufacturer's protocol. Then, the mixed binding reactions were electrophoresed in a 6% polyacrylamide gel, transferred to Hybondt-N þ membrane (Amersham Pharmacia Biotech) and cross-linked to the membrane with 120 mJ/ cm 2 UV. The detection was performed using Chemiluminescent Nucleic Acid Detection Module (Pierce Biomedical Company) following the manufacturer's protocol.
Luciferase reporter assay Cells were seeded in six-well plates at a density of 1 Â 10 5 /well 24 h before transfection. Then, cells were transfected with either pNF-kB-Luc Vector(Clontech) or pTAL-Luc Vector (Clontech) as transfection efficiency control using Lipofectamine and Plus Reagents (Invitrogen) according to the manufacturer's protocol. After 24 h, cell lysates were prepared and luciferase activity was measured using a Luciferase Reporter Assay Kit (BioVision) according to the manufacturer's protocol. Transcriptional activity of NF-kB was calculated as relative luciferase activity normalized by transfection efficiency of control. Experiments were independently repeated three times in triplicate.
Cell treatment in the NF-kB inhibition assay For inhibition of NF-kB activity, cells were pretreated with or without 2 mM Bay11-7085 (Calbiochem, San Francisco, CA, USA) under serum-free conditions for 1 h, and then exposed to each experimental condition.
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